Bisphosphonate
Pamidronate disodium
Brand names: Aredia
Adult dose
Dose: Hypercalcaemia of malignancy: 30–90mg IV infusion (rate ≤60mg/h, max concentration 60mg/250mL). Bone metastases: 90mg IV every 4 weeks
Route: IV
Frequency: per indication
Dose adjustments
Renal
Avoid if eGFR <30; reduce infusion rate
Clinical pearls
- Hypercalcaemia of malignancy, multiple myeloma bone disease, Paget's disease
- Dental review before; correct vitamin D + calcium before
Contraindications
- Severe renal impairment
- Hypocalcaemia
- Hypersensitivity
Side effects
- Acute-phase reaction (flu-like, 24–48h post first dose)
- Hypocalcaemia
- Hypophosphataemia
- Renal impairment
- Osteonecrosis of jaw
- Atypical femoral fracture
- Uveitis
Interactions
- Loop diuretics (additive hypocalcaemia)
Monitoring
- Calcium
- U&E
- Phosphate
Reference: BNF; NICE; https://bnf.nice.org.uk/drugs/pamidronate-disodium/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016